gut microbiome
Around two in five Malaysians are said to have metabolic syndrome.
It will use the funds to deepen its presence across Asia.
The clinical trial results will be used to expand Viome’s mRNA platform, which in May received FDA breakthrough device designation for identifying early signs of oral and throat cancers.
The company, formerly named Thryve, also hired a new CEO and a chief product officer.
The partnership expands on the companies’ earlier collaboration announced in late 2019.
Viome has adapted its technology to search for the presence of oral squamous cell carcinoma and oropharyngeal cancer in users’ saliva samples.